Michael Michaud's  Instablog

Michael Michaud
Send Message
Michael Michaud is the founder of Invest2Success.com (http://www.invest2success.com/) and the Invest2Success Blog (http://invest2success.blogspot.com/). He has been investing and trading in the financial markets since 1989. He founded Invest2Success.com to empower individual institutional... More
My company:
Invest2Success
My blog:
Invest2Success Blog
  • Amgen To Set Up JV In China 0 comments
    May 19, 2013 8:10 PM | about stocks: AMGN, BMY, LLY, ANIK, JNJ, NVS, TEVA, BIIB, GILD, TMO, AGN, MYL, PFE, GSK, SNY

    Amgen Zhejiang Joint Venture

    Amgen to Set Up JV in China - By Zacks Investment Research

    Amgen (NASDAQ:AMGN) recently announced its intention to set up a joint venture (JV) in China with Zhejiang Beta Pharma Co., Ltd. The JV will focus on the commercialization of Amgen's colorectal cancer drug, Vectibix, in China.

    While Zhejiang Beta Pharma will hold a 51% stake in the JV, Amgen-Beta Pharmaceuticals Co., the balance will be held by Amgen. The setting up of the JV depends on the satisfaction of closing conditions including approval from the concerned government authorities in China.

    The JV should benefit from Zhejiang Beta Pharma's development capabilities as well as its strong oncology sales network in China.

    This agreement is in line with Amgen's strategy of expanding its presence across the world. Earlier this year, Amgen had announced its intention to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore. The company expects to manufacture both clinical as well as commercial products in this facility.

    Meanwhile, earlier ithis month, Amgen reported encouraging data on Vectibix from the phase III head-to-head ASPECT study. The study compared Vectibix with Eli Lilly/Bristol-Myers Squibbs' (NYSE:LLY) / (NYSE:BMY) Erbitux as a monotherapy treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors. Results showed that Vectibix was non-inferior to Erbitux for overall survival.

    Adverse events included rash, diarrhea and hypomagnesemia. Amgen will present detailed results from this study at an upcoming meeting later this year.

    Vectibix' label expansion would help boost product sales. Vectibix sales came in at $359 million in 2012, up 11.5%.

    Amgen currently carries a Zacks Rank #3 (Hold). At present, Anika Therapeutics Inc. (NASDAQ:ANIK) , a Zacks Rank #1 (Strong Buy) stock, looks well-positioned.

    Profit Rocket

    Invest2Success China Hong Kong "Profit Rockets" Stock Picks
    Subscription Email Service

    Free Trial - Receive daily low-risk high-reward momentum stock picks every day that include buy entry, stop-loss, take profit area targets, and trade management information on China and Hong Kong equities to your email inbox.

    Morningstar Asia

    Morningstar Asia Investment Research Free Trial

    Asia Pacific Financial Forecast

    Asian-Pacific Financial Forecast

    Asia-Pacific Markets

    Intraday Forecasts on the Hang Seng, Nikkei 225, MSCI Singapore, ASX 200, STI, Kospi 200, MSCI Taiwan Stocks
    You get short, clear forecasts for the direction throughout the trading session, most with short-term Elliott wave-labeled charts. And you get precise support and resistance points, so you always stay in control of your position risk.

    Stocks: AMGN, BMY, LLY, ANIK, JNJ, NVS, TEVA, BIIB, GILD, TMO, AGN, MYL, PFE, GSK, SNY
Back To Michael Michaud's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.